Ocean Biomedical's Novel Cancer Immunotherapy Shows Promise in Reversing EGFR-TKI Resistance in Lung Cancer
Ocean Biomedical's breakthrough research demonstrates their immunotherapy candidates can synergize with tyrosine kinase inhibitors like osimertinib to suppress tumor growth in EGFR-mutant lung cancer.
Ocean Biomedical Secures $3.5M NIH Grant to Advance Novel Malaria Vaccine Development
Ocean Biomedical's research team, led by Dr. Jonathan Kurtis, has received $3.5 million in NIH funding to advance their innovative malaria vaccine research targeting the GARP protein.